merial deal in final stages remlin

The commitment shown by Merial demonstrates the large commercial and profit potential of the Imugene products. In addition, the signing of commercial contracts with such an industry leader also validates the Adenoviral Delivery Vector.

The above partnering arrangements are part of Imugene’s initial commercialisation strategy to sublicense certain developed products to gain early cashflow. While the commercial terms relating to the above agreements are confidential, the Imugene group has received initial sign up payments, then there will be several milestone based payments as the products progress through regulatory evaluation and approval process, finally there will ongoing royalty payments from the product sales for the life of the patents. These agreements, allow Imugene to focus on other products within its portfolio that are ready for commercialisation.